December 29, 2017 / 9:08 PM / a year ago

BRIEF-Bio Path Holdings Provides Clinical Update And 2018 Business Outlook

Dec 29 (Reuters) - Bio Path Holdings Inc:

* BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2018 BUSINESS OUTLOOK

* BIO PATH HOLDINGS INC - ‍ANNOUNCES INITIATION OF ITS PHASE 2A CLINICAL STUDY OF PREXIGEBERSEN FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA​

* BIO PATH HOLDINGS INC - INTENDS TO INITIATE A PHASE 1 CLINICAL TRIAL OF BP1002 IN 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below